SHL reaches a new milestone of 2000 employees in Taiwan
pharmafile | October 7, 2013 | News story | Manufacturing and Production | auto injector, roger samuelsson, shl growth, shl milestone
SHL, the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices, officially announced reaching a new milestone of 2,000 employees in Taiwan as of September 1st 2013. With the company’s continuous investments in new manufacturing equipment and recent facility expansions in Taiwan to support growing customer demands, this number has already grown since September and is expected to increase even more within the next few months. This new milestone also means that SHL now has a total of 2,500 employees worldwide, with 500 staff located throughout the company’s other sites in the USA, Sweden and China.
SHL announced one of its first major milestones of reaching 1,000 employees world-wide back in 2004 and has more than doubled that number since. Various other milestones such as signing a LOI (Letter of Intent) for a $100 million USD of investment in Taiwan in 2008 followed by a second LOI for an additional $40 million USD investment this year, winning various product awards and establishing new production centers in Taiwan and Florida were also achieved within a few short years thereafter. SHL remains determined to grow and invest appropriately in order to maintain its leadership position in the field of auto injectors for the biopharmaceutical industry.
Reflecting on this new milestone, SHL President and CEO Roger Samuelsson comments, “We’ve come a long way since the company was first established in 1989 and I am excited to announce reaching such a significant milestone here at our Taiwan facilities. We’ve been very fortunate to attract so many talented staff from throughout the world and we look forward to further expanding our operations in Taiwan as well as globally to address and efficiently meet the needs of our customers.”
As a result of SHL’s accomplishments in recent years, the company’s customer base now includes 80% of the world’s top 25 biopharmaceutical companies, with various SHL developed drug delivery devices often used as industry benchmarks and several new devices being launched recently.
Related Content
Novartis secures US rights to Adamis’ epinephrine auto injector
Novartis has penned an agreement with Adamis Pharmaceuticals to commercialise and distribute the latter’s epinephrine …
FDA unveils guidelines to help generic medical device versions reach the market
The scandal surrounding Mylan’s price-hiking of its flagship EpiPen epinephrine auto-injector was the news of …
SHL brings innovation to Pharmapack Europe 2017
As a forward-looking company with extensive knowledge and experience, SHL delivers solutions for today on …
